Further to the above, preclinical data suggest that combined PI3Kβ/δ and mTOR targeting with AZD8186 and AZD2014, respectively, may overcome resistance to PI3Kβ/δ inhibition and completely prevent outgrowth of lymphoma cells in vivo in cell line- and patient-derived xenograft mouse models of DLBCL. Here, MTOR is linked to diffuse large B-cell lymphoma.